These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 18094383)

  • 1. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Ekberg H; Tedesco-Silva H; Demirbas A; Vítko S; Nashan B; Gürkan A; Margreiter R; Hugo C; Grinyó JM; Frei U; Vanrenterghem Y; Daloze P; Halloran PF;
    N Engl J Med; 2007 Dec; 357(25):2562-75. PubMed ID: 18094377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 4. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
    Smith JM; Nemeth TL; McDonald RA
    Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Toward an evidence-based immunosuppression].
    Pascual J
    Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
    Ekberg H; Bernasconi C; Tedesco-Silva H; Vítko S; Hugo C; Demirbas A; Acevedo RR; Grinyó J; Frei U; Vanrenterghem Y; Daloze P; Halloran P
    Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
    Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
    [No Abstract]   [Full Text] [Related]  

  • 9. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.
    Vincenti F
    Transplant Proc; 2001 Jun; 33(4 Suppl):11S-18S. PubMed ID: 11406263
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunosuppression for kidney transplant recipients: current strategies].
    Alberú J; Urrea EM
    Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F
    Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract]   [Full Text] [Related]  

  • 12. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
    Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
    [No Abstract]   [Full Text] [Related]  

  • 13. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
    Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
    Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immunossupresive drugs in renal transplantation].
    Baczkowska T; Durlik M
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():99-120. PubMed ID: 15669207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Krämer BK; Jung B; Banas B
    N Engl J Med; 2008 Jun; 358(23):2519; author reply 2519-20. PubMed ID: 18536098
    [No Abstract]   [Full Text] [Related]  

  • 17. Can we maintain immunosuppression avoiding nephrotoxic agents in pancreas transplantation?
    Kandaswamy R; Dunn T; Humar A; Sutherland DE
    Transplant Proc; 2008 Mar; 40(2):516-7. PubMed ID: 18374118
    [No Abstract]   [Full Text] [Related]  

  • 18. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inferior results with basis immunosuppression with sirolimus in kidney transplantation.
    van den Akker JM; Hené RJ; Hoitsma AJ
    Neth J Med; 2007 Jan; 65(1):23-8. PubMed ID: 17293636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation.
    Ciancio G; Mattiazzi A; Miller J; Burke GW
    Minerva Urol Nefrol; 2003 Mar; 55(1):43-56. PubMed ID: 12773966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.